• Je něco špatně v tomto záznamu ?

The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells

Starkova J, Madzo J, Cario G, Kalina T, Ford A, Zaliova M, Hrusak O, Trka J

. 2007 ; 13 (6) : 1726-1735.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc07526550

Grantová podpora
NR8316 MZ0 CEP - Centrální evidence projektů

PURPOSE: Chimeric transcription factor ETV6/RUNX1 (TEL/AML1) is believed to cause pathologic block in lymphoid cell development via interaction with corepressor complex and histone deacetylase. We wanted to show the regulatory effect of ETV6/RUNX1 and its reversibility by histone deacetylase inhibitors (HDACi), as well as to identify potential ETV6/RUNX1-regulated genes. EXPERIMENTAL DESIGN: We used luciferase assay to show the interaction of ETV6/RUNX1 protein, ETV6/RUNX1-regulated gene, and HDACi. To identify ETV6/RUNX1-regulated genes, we used expression profiling and HDACi in lymphoid cells. Next, using the flow cytometry and quantitative reverse transcription-PCR, we measured differentiation changes in gene and protein expression after HDACi treatment. RESULTS: Luciferase assay showed repression of granzyme B expression by ETV6/RUNX1 protein and the reversibility of this effect by HDACi. Proving this regulatory role of ETV6/RUNX1, we identified, using complex statistical analysis, 25 genes that are potentially regulated by ETV6/RUNX1 protein. In four selected genes with known role in the cell cycle regulation (JunD, ACK1, PDGFRB, and TCF4), we confirmed expression changes after HDACi by quantitative analysis. After HDACi treatment, ETV6/RUNX1-positive cells showed immunophenotype changes resembling differentiation process compared with other leukemic cells (BCR/ABL, ETV6/PDGFRB positive). Moreover, ETV6/RUNX1-positive leukemic cells accumulated in G(1)-G(0) phase after HDACi whereas other B-lineage leukemic cell lines showed rather unspecific changes including induction of apoptosis and decreased proliferation. CONCLUSIONS: Presented data support the hypothesis that HDACi affect ETV6/RUNX1-positive cells via direct interaction with ETV6/RUNX1 protein and that treatment with HDACi may release aberrant transcription activity caused by ETV6/RUNX1 chimeric transcription factor.

000      
00000naa 2200000 a 4500
001      
bmc07526550
003      
CZ-PrNML
005      
20131015144834.0
008      
090727s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Starková, Júlia, $d 1977- $7 xx0106984
245    14
$a The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells / $c Starkova J, Madzo J, Cario G, Kalina T, Ford A, Zaliova M, Hrusak O, Trka J
314    __
$a Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology/Oncology, 2nd Medical School, Charles University Prague, Prague, Czech Republic
520    9_
$a PURPOSE: Chimeric transcription factor ETV6/RUNX1 (TEL/AML1) is believed to cause pathologic block in lymphoid cell development via interaction with corepressor complex and histone deacetylase. We wanted to show the regulatory effect of ETV6/RUNX1 and its reversibility by histone deacetylase inhibitors (HDACi), as well as to identify potential ETV6/RUNX1-regulated genes. EXPERIMENTAL DESIGN: We used luciferase assay to show the interaction of ETV6/RUNX1 protein, ETV6/RUNX1-regulated gene, and HDACi. To identify ETV6/RUNX1-regulated genes, we used expression profiling and HDACi in lymphoid cells. Next, using the flow cytometry and quantitative reverse transcription-PCR, we measured differentiation changes in gene and protein expression after HDACi treatment. RESULTS: Luciferase assay showed repression of granzyme B expression by ETV6/RUNX1 protein and the reversibility of this effect by HDACi. Proving this regulatory role of ETV6/RUNX1, we identified, using complex statistical analysis, 25 genes that are potentially regulated by ETV6/RUNX1 protein. In four selected genes with known role in the cell cycle regulation (JunD, ACK1, PDGFRB, and TCF4), we confirmed expression changes after HDACi by quantitative analysis. After HDACi treatment, ETV6/RUNX1-positive cells showed immunophenotype changes resembling differentiation process compared with other leukemic cells (BCR/ABL, ETV6/PDGFRB positive). Moreover, ETV6/RUNX1-positive leukemic cells accumulated in G(1)-G(0) phase after HDACi whereas other B-lineage leukemic cell lines showed rather unspecific changes including induction of apoptosis and decreased proliferation. CONCLUSIONS: Presented data support the hypothesis that HDACi affect ETV6/RUNX1-positive cells via direct interaction with ETV6/RUNX1 protein and that treatment with HDACi may release aberrant transcription activity caused by ETV6/RUNX1 chimeric transcription factor.
650    _2
$a apoptóza $x účinky záření $7 D017209
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a protein PEBP2A2 $x fyziologie $x genetika $7 D050676
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u leukemie $x účinky léků $7 D015973
650    _2
$a granzymy $x genetika $7 D053804
650    _2
$a histondeacetylasy $7 D006655
650    _2
$a lidé $7 D006801
650    _2
$a lymfoidní leukemie $x genetika $x patologie $7 D007945
650    _2
$a lymfopoéza $x genetika $x účinky léků $7 D038041
650    _2
$a protoonkogenní proteiny c-ets $x fyziologie $x genetika $7 D050783
650    _2
$a represorové proteiny $x fyziologie $x genetika $7 D012097
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a inhibitory histondeacetylas $7 D056572
700    1_
$a Madžo, Jozef, $d 1976- $7 xx0037668
700    1_
$a Cario, Gunnar
700    1_
$a Kalina, Tomáš, $d 1975 říjen 11.- $7 xx0060125
700    1_
$a Ford, Anthony
700    1_
$a Žaliová, Markéta, $d 1979- $7 xx0074371
700    1_
$a Hrušák, Ondřej, $d 1965- $7 xx0036691
700    1_
$a Trka, Jan, $d 1966- $7 xx0036261
773    0_
$w MED00001121 $t Clinical cancer research $g Roč. 13, č. 6 (2007), s. 1726-1735 $x 1078-0432
910    __
$a ABA008 $b x $y 7 $z 0
990    __
$a 20090726182400 $b ABA008
991    __
$a 20131015145416 $b ABA008
999    __
$a ok $b bmc $g 670189 $s 528946
BAS    __
$a 3
BMC    __
$a 2007 $b 13 $c 6 $d 1726-1735 $i 1078-0432 $m Clinical cancer research $x MED00001121
GRA    __
$a NR8316 $p MZ0
LZP    __
$a 2009-B3/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...